Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment by unknown
POSTER PRESENTATION Open Access
Inflence of clinical and genetic characteristics on
ability to achive and maintain remission in JIA
patients on etanercept treatment
Dragana S Lazarevic1*, Jelena Vojinovic1, Gordana Susic2, Jelena Basic3
From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014
Introduction
There are no official published recommendations how
and when to stop treatment with biologics when remis-
sion achieved.
Objectives
Primary objective of this study was to evaluate influence
of JIA subtype and duration of metotrexate (MTX) and
steroids treatment on time to achieve and ability to main-
tain remission in JIA patients on biologic treatment. The
second aim was to establish if there is contribution of
tumor necrosis factor ά (TNFά–308) promoter and FokI
vitamin D receptor (VDR) polymorphism on clinical out-
come and possibility to discontinue treatment in JIA
patients treated with biologics.
Methods
68 JIA patients treated with etanercept from Serbian
biologic registry were included and retrospective data
analysis performed. Genomic DNA was extracted from
blood samples and TNFά–308 promoter and FokI VDR
polymorphism was evaluated using the PCR-RFLP
method. Disease subtypes, activity and treatment efficacy
were collected during six years follow-up period in
intervals after commencing etanercept: 6 months, 1 year
and annually thereafter. Disease remission, as a condi-
tion to stop biologic treatment, was defined using Wal-
lace and all criteria [1].
Results
At enrolment JIA patients mean age were 183.34±60,
58 months, disease duration 70.29±44,57 months, average
dose of MTX 13.85±4.47 mg/m2/week. Etanercept treat-
ment could be stopped after 42.66±21.64 months with sus-
tained remission during the next 30.33±21.04 months.
Therapy resistant patients required higher doses of MTX
for a longer period, with statistically significance in sys-
temic JIA (15.97±3.56 vs. 13.15±4.55, p=0.016). Remission
in this patients was shorter and they needed retreatment
with biologics (16.31±18.55 vs. 35.80±19.53, p=0.001) due
to disease worsening. Treatment inefficacy was present in
systemic JIA with the longest etanercept treatment 59.50
±5.97 and shortest remission 17.67%±9.82, while etaner-
cept therapy was the most effective in RF- JIA patients.
There was no statistically significant difference in cumula-
tive dose of steroids in different JIA subtypes. The distri-
bution of TNFά–308 (GG, GA, AA) and FokI VDR
genotypes (FF,Ff, ff) was not significantly different among
JIA subtypes. After six years follow up period 37(54.5%)
patients were in remission (20 patients with FF+GA and
17 patients with Ff+GA polymorphism). Associate pre-
sence of FF+GA genotype was present more frequently in
patients who needed longer treatment and have had
shorter remission time.
Conclusion
JIA patients needing higher MTX doses to control disease
and have associated presence of GA+FF polymorphisms
(for TNFά–308 promoter and FokI VDR, respectively)
have less chances to achieve and sustain remission off
biologics, especially in systemic JIA..
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